MetLife (NYSE: MET) director adds 11 shares via dividend reinvestment
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
A MetLife, Inc. director reported a small increase in holdings through automatic dividend reinvestment under the company’s Deferred Compensation Plan for Non-Management Directors. On 12/09/2025, the director acquired 11 shares of MetLife common stock at $77.82 per share via an imputed reinvestment of dividends on deferred shares. Following this transaction, the director beneficially owns 1,469 shares of MetLife common stock in direct form. The transaction was reported on a Form 4 as required for company insiders.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mumenthaler Christian Stephane
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 11 | $77.82 | $856.02 |
Holdings After Transaction:
Common Stock — 1,469 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did MetLife (MET) report in this Form 4?
A MetLife, Inc. director reported acquiring 11 shares of MetLife common stock on 12/09/2025 through dividend reinvestment under a deferred compensation plan.
What is the MetLife Deferred Compensation Plan for Non-Management Directors?
The plan allows non-management directors to defer receipt of MetLife, Inc. common stock; in this case, dividends on deferred shares were imputed and reinvested into additional deferred shares.
Was this MetLife (MET) insider transaction a purchase on the open market?
No. The Form 4 explains that the 11 shares resulted from imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors.
What type of filing reported this MetLife (MET) insider activity?
The insider activity was reported on an SEC Form 4, which discloses changes in beneficial ownership by directors, officers, and certain shareholders.